Recital 121, Decision_act (EU) 2018/9019

In forcesince 29 Oct 2018

Another competitor noted that Mars would, post-Transaction, sell its own

products in the AniCura clinics, reducing the available retail outlets for its competitors: "With the acquisition of AniCura by Mars we expect that a number

128 Non-Horizontal Merger Guidelines, paragraph 70.

129 Non-Horizontal Merger Guidelines, paragraph 72.

130 Response to RFI to Competitors, question 4. of clinics will take on Mars/Royal Canin’s pet food products, thereby reducing opportunities for [COMPETITOR] and other pet food competitors. Mars will most probably influence which pet foods the vet clinics in AniCura will use and/or sell."131 Similar concerns were raised by veterinarians contacted during the market investigation, for example: “It is quite clear that Mars would push their own food lines into “their” clinics, so competition in the market would be reduced.” Another one mentioned, “AniCura-member clinics may sell only Royal Canin products and by this strengthens the brand.”132